Download Pathogenomics in France - ERA

Pathogenomics in France
Philippe Glaser
Administrative situation
• Creation of the ANR (Agence National pour la
Recherche) - National Research Agency
–
–
–
–
–
–
Delay due to the need of a law
Headed by Gilles Bloch
Budget 350 M€
Infectious diseases is one of the priority
Financial basis for future transnational program
BUT the administrative person in charged of this topic
is not nominated
Research agenda-situation in France
• All major pathogenic species are studied in France, a
weakness on streptococci (>80 teams)
• The different fields of the agenda from ecology and
epidemiology to cell microbiology are covered
• Fundamental and applied research + development
(innovation)
• Genomics platforms
– Sequencing facility (CNS, Institut Pasteur, Marseille)
– Transcriptome platforms (production and scanning)
– Proteome analysis
– Weakness: metabolome analysis
• Few screens of active molecules (inhibitors)
• Research teams in the filed of Pathogenomics
belong to various administrative structures:
–
–
–
–
–
–
–
–
INSERM
INRA
CNRS
Institut Pasteur
CEA
Universities
Hospitals
Industries
Need to improve networking and collaborations
Interaction with SMEs and Pharma
Many French teams are involved in
European collaborations
• Bilateral collaboration
• Part of existing European networks (NoE,
IP, STREP)
• Contribute to the submission of project
which have not been retained
Collaboration - Genomics
• Analysis of the need of new genome sequences
(environmental samples, hyper-virulent clones …)
• Information exchange and common genomic
databases (also before submission to public
sequence databases)
• Cooperation in genome annotation and reannotation (species-genome)
• The human metagenome
Transcriptomics - proteomics metabolomics
• Exchange of sets of oligonucleotides for major microorganisms.
Improvement of the quality (there is a need).
• Chips production and exchange
• Other technical development in the field of transcriptomics and
proteomics
• Data exchange and databases (difficult issue)
• Strengthening metabolomics
• Access to platform for the screening of diverse chemical compounds
collections
• Production and exchange of transgenic mice
• Stimulate the production and exchange of other tools and
methodological improvements
Expectations from this transnational call
•
•
•
•
•
•
•
•
•
Improve the evaluation of the project
Stimulatory effect on the quality of the projects
Create opportunities for new collaborations
Provide the opportunity to initiate new research projects
Opportunities for junior groups to be involved in international
collaborations
How to define the link with genomics?
Increase the financial investment of the French research agency in
this field.
How to synchronize with national calls?
What should be the priority topics?